Panobinostat
HDAC inhibitor / A potent inhibitor of class I and II HDACs1. Cotreatment with panobinostat and an HSP90 inhibitor caused synergistic apoptosis in human CML-BC and AML cells2. A potent antimyeloma agent that overcomes drug resistance3.
Biochemicals & reagents
404950-80-7
LBH-589
1) Geng et al. (2006), Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer; Cancer Res., 66 11298 2) George et al. (2005), Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3; Blood, 105 1768 3) Maiso et al. (2006), The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance; Cancer Res., 66 5781
-20°C
TARGET: Protein deacetylase -- PATHWAY: Chromatin; Posttranslational modification; Apoptosis inducer -- RESEARCH AREA: Epigenetics; Cell death -- DISEASE AREA: Cancer